
zzso is a new zzso agent with a broad spectrum of zzso The purpose of this Phase I trial was to define the maximum tolerated dose of zzso when added to the widely used combination of zzso and zzso 

Patients with advanced cancer that was zzso or resistant to standard treatments were treated with zzso zzso and zzso doses were escalated in sequential zzso of zzso After definition of the maximum tolerated dose without zzso zzso stimulating factor zzso was added and further dose escalation was zzso 

The maximum tolerated doses were: zzso 135 zzso as a zzso intravenous zzso infusion on Day 1; zzso area under the curve zzso on Day 1; and zzso zzso zzso zzso on Days 1, 2, and 3; the regimen was repeated every 21 zzso zzso particularly zzso was the zzso toxicity with this zzso zzso zzso toxicity was zzso The addition of zzso did not allow substantial dose escalation because zzso was zzso by this zzso Eleven of 25 patients had major responses to this zzso including 8 of 14 patients with previously treated small cell lung zzso 

The combination of zzso zzso and zzso is zzso although only relatively low doses of all three drugs can be tolerated due to zzso This regimen showed a high level of activity in these patients with zzso cancer, and merits further zzso 

